Lebrikizumab Maintains Skin Clearance Through 3 Years in AD Patients: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On June 6, 2025, we reported on a study presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference that evaluated the long-term safety and efficacy of lebrikizumab (Ebglyss) in people with moderate to severe atopic dermatitis (AD).

The study

The ADjoin extension study evaluated people aged 12 years and older who had achieved clinical response (IGA 0/1 or EASI 75) at week 16 in the phase 3 ADvocate1 and ADvocate2 trials. Responders were randomized to receive lebrikizumab 250 mg every 2 weeks (Q2W) or every 4 weeks (Q4W) through 152 weeks. Baseline demographics were balanced between groups: the mean age was approximately 36 years, with a mean disease duration of over 22 years. About 14% of participants were adolescents.

The findings

Among week 16 responders, approximately 80% maintained a deep clinical response, defined as EASI 90, through week 152. Additionally, more than 50% of participants achieved complete skin clearance, assessed by either EASI 100 or IGA 0. These results were consistent across both dosing regimens.

Notably, most participants (across both Q2W and Q4W arms) did not require rescue therapy, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), or systemic therapies, during the 3-year treatment period. Rescue medication use was permitted in the long-term extension phase on a case-by-case basis.

Improvement in health-related quality of life was also sustained. Approximately one-third of participants reported minimal to no AD-specific symptoms at week 152, as measured by the Patient-Oriented Eczema Measure (POEM) with scores of 0 or 1.

Authors' comments

"These 3-year data suggest that long-term maintenance of total skin clearance is an achievable treatment goal for at least half of lebrikizumab Week 16 monotherapy responders."

Click here for more details.